Overview
Company Does Not Provide H-1B Sponsorship
Earli develops a cancer diagnostic platform that uses synthetic biology to create Synthetic Bioclassifiers. These genetic constructs enter cells and, if a cell is cancerous, activate to make the cell produce a biomarker that is released into the bloodstream for detection. The system is programmable to distinguish cancerous from healthy cells, addressing the limits of traditional liquid biopsies by prompting cancer cells to reveal themselves. It plans to commercialize this platform through partnerships with healthcare providers and pharmaceutical companies, with Accenture as a strategic investor.
Work here?Claim your company
Simplify's take
What believers are saying
- Earli raised another $44M in 2026, bringing total funding to $104M.
- Earli plans a Phase 1/2 lung cancer trial by mid-2027.
- Australia trial sites expanded to Sydney, Melbourne, Frankston, and Adelaide.
What critics are saying
- Earli's Phase 1 tested only ten patients, so performance remains unproven.
- STRIDE-RCT's 20,000-patient NHS trial advances competing blood-based early-detection validation.
- If synthetic biomarkers miss early tumors, Earli's platform becomes commercially irrelevant.
What makes Earli unique
- Earli forces cancer cells to emit biomarkers using synthetic bioclassifiers, not passive liquid biopsies.
- Its platform combines AI-designed genetic switches with transient nanoplasmids and LNP delivery.
- Founders include Cyriac Roeding and late Stanford cancer biologist Sanjiv Sam Gambhir.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards